207 related articles for article (PubMed ID: 21935931)
1. Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
Yang KT; Wang MC; Chen JY; Hsu MC; Hung WC
J Cell Physiol; 2011 Nov; 226(11):2849-56. PubMed ID: 21935931
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
3. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
5. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
Tomoda K; Kato JY; Tatsumi E; Takahashi T; Matsuo Y; Yoneda-Kato N
Blood; 2005 Jan; 105(2):775-83. PubMed ID: 15353483
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
[TBL] [Abstract][Full Text] [Related]
9. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
[TBL] [Abstract][Full Text] [Related]
10. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Huang Q; Yang Y; Li X; Huang S
Tumour Biol; 2011 Dec; 32(6):1191-7. PubMed ID: 21892628
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
14. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
Komatsu N; Watanabe T; Uchida M; Mori M; Kirito K; Kikuchi S; Liu Q; Tauchi T; Miyazawa K; Endo H; Nagai T; Ozawa K
J Biol Chem; 2003 Feb; 278(8):6411-9. PubMed ID: 12456669
[TBL] [Abstract][Full Text] [Related]
15. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M
Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
20. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]